Families living with Alexander disease have had one option for as long as the condition has been recognized, which is to manage symptoms and watch the disease advance. That changed on September 3.
The Food and Drug Administration approved Zanvastro, known generically as zilganersen, for the treatment of Alexander disease in children and adults. It is the first approved therapy for the condition and the first designed to act on the protein buildup that drives it rather than the symptoms it produces.
Until now, "there have been no approved treatment options, only supportive care while the disease progresses," said Emily Freilich, M.D., director of the Division of Neurology I in the agency's Center for Drug Evaluation and Research. She called the decision a landmark moment for the community.
A Protein That Turns on the Cells Meant to Protect the Brain
Alexander disease is caused by mutations in the gene that produces glial fibrillary acidic protein, usually shortened to GFAP. When that protein is abnormal, it accumulates inside astrocytes, the support cells that keep neurons functioning, and the damage compounds over time.
The agency describes the disease as affecting fewer than one in a million people. It can begin in the first weeks of life or emerge in adulthood, and its effects reach across seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure inside the brain.
Zanvastro is an antisense oligonucleotide, a class of drug that interferes with the genetic instructions a cell uses to build a protein. Rather than clearing GFAP that has already accumulated, it reduces how much of the abnormal protein gets produced in the first place. It is given as an injection into the spinal canal once every three months by a trained clinician, a route that delivers the drug directly to the central nervous system.
The Evidence Behind a Decision Covering Infants Through Adults
The approval rests on a multicenter, randomized, controlled study that enrolled 49 patients aged two and older, alongside an open-label substudy of four patients younger than two. Those are small numbers by the standards of most drug approvals, and they reflect how few people have the disease.
Among patients aged five and older who had measurable trouble walking at the start, those treated with the drug showed significantly better walking speed at 61 weeks than those who received no treatment. In children aged two to four, where walking speed is not a dependable measure, investigators used a broader assessment covering standing, walking, running and jumping. Treated children improved on that measure while the control group declined.
For infants under two, direct trial data were limited. Regulators relied on pharmacokinetic modeling showing that drug levels in that age group are expected to resemble those in older children at the same dose, supported by safety findings in the four youngest patients and in older pediatric participants. That reasoning is what allowed the indication to reach from infancy through adulthood on an unusually thin evidence base, and it is worth stating plainly rather than leaving in a footnote.
The most common side effects reported were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has been reported in treated patients, and the agency advises patients and caregivers to tell a clinician if symptoms consistent with meningitis develop.
The Distance Between an Approval and a Prescription
An approval is not the same as availability, and families should expect a gap. The manufacturer, Ionis Pharmaceuticals, has said the drug will reach the United States in the coming weeks and that it will offer patient support services including help navigating insurance approval and information on affordability programs.
Cost has not been disclosed publicly. Intrathecal antisense therapies for rare neurological conditions have historically carried high annual prices, and coverage decisions for an ultra-rare indication typically involve prior authorization and case-by-case review rather than routine approval. Households facing that process can ask a treating neurologist about prior authorization support, appeals, and manufacturer assistance programs before assuming a denial is final.
Access outside the United States is a separate question. Ionis licensed rights outside the country to Recordati, and regulatory submissions in Europe and Japan are expected in 2027. Families abroad should not read this approval as immediate availability where they live.
Several things remain unknown. The pivotal comparison measured walking speed and motor function over 61 weeks, so the durability of benefit over many years has not been established. Whether treatment started in infancy changes the long-term course of the disease is an open question that the available data cannot answer. And because the disease is so rare, post-marketing experience will accumulate slowly.
The Value of an Approval in a Disease Almost Nobody Has Heard Of
The drug received orphan drug, fast track, breakthrough therapy and rare pediatric disease designations, and the agency granted a rare pediatric disease priority review voucher alongside the decision. Those programs exist because the commercial case for developing a therapy for fewer than one in a million patients is otherwise difficult to make.
For the broader public, that is the useful takeaway. Most readers will never meet someone with Alexander disease. But the regulatory machinery that produced this decision, including the willingness to extend an indication to infants on modeling rather than trial data, is the same machinery that governs treatments for many other rare conditions where families face the same wait.
Anyone whose family is affected should discuss whether treatment is appropriate with a neurologist familiar with the condition, review the full prescribing information, and ask specifically about monitoring for meningitis symptoms after each dose. This article is general information and is not a treatment recommendation.
Key Questions Answered
What was approved? Zanvastro, generically zilganersen, is an antisense oligonucleotide for the treatment of Alexander disease in pediatric and adult patients. It is the first approved therapy for the condition.
What is Alexander disease? A rare, progressive neurological disorder caused by mutations in the GFAP gene. Abnormal protein accumulates in the brain's supportive cells, causing damage over time. The agency describes it as affecting fewer than one in a million people.
How is the drug given? As an injection into the spinal canal every three months, administered by a trained health care professional.
Does it cure the disease? No. In the trial, treated patients showed better walking speed and motor function compared with untreated participants over 61 weeks. Long-term outcomes have not been established.
What are the known side effects? Vomiting, back pain, cough, headache, and post-lumbar puncture syndrome were most common. Aseptic meningitis has been reported, and symptoms consistent with meningitis should be reported to a clinician promptly.
When will it be available and what will it cost? The manufacturer says it will be available in the United States in the coming weeks. Pricing has not been publicly disclosed. Patient support services, including insurance navigation, have been announced.
Is it available outside the United States? Not yet. Regulatory submissions in Europe and Japan are expected in 2027 through a licensing partner.
